A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
A Study of LGK974 in Patients With Cancer
Sponsor: Novartis Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAT0131
U.S. Govt. ID: NCT01351103
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This primary purpose of this study is to find the recommended dose of LGK974 and PDR001 that can be safely given to adult patients who have advanced metastatic pancreatic cancer, or triple negative breast (TNB) cancer, or melanoma, lung squamous cell cancer, esophageal squamous cell cancer, cervical squamous cell cancer, or head and neck squamous cell cancer (HNSCC).
This study is closed
Richard Carvajal, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have a diagnosis of advanced or metastatic cancer that has progressed despite standard therapy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator